Neurodegenerative Disease Drug Screening

Neurodegenerative disease drug screening services offer an efficient platform developing treatments for diseases such as Alzheimer's disease and Parkinson's disease. By using Caenorhabditis elegans as a disease model, we can rapidly assess candidate drugs’ protective effects on the nervous system, their potential to improve neurological function, and the inhibitory effect on disease progression. Observing drug effects on neurodegenerative lesions, neuronal function, protein aggregation enables us to identify potential therapeutic drugs. Our services integrate advanced screening technology with precise behavioral analysis, accelerating drug discovery and verification for neurodegenerative diseases.

Our services include but are not limited to:

Ø  Anti-Alzheimer's Disease Drug Screening Service

Through the C. elegans Alzheimer's disease model, we screen potential drugs that reduce amyloid accumulation, alleviate nerve paralysis, and improve cognitive function. This service is ideal for early drug development and neuroprotection research.

Ø  Anti- Parkinson's Drug Screening Service

Our Parkinson’s disease model in C. elegans evaluates candidate drugs for their ability to protect dopamine neuron and restore motor function, providing vital insights for Parkinson's treatment development.

Ø  Anti-Huntington's Disease Drug Screening Service

Through the C. elegans Huntington's disease model, we identify drugs that mitigate neurodegeneration and movement disorders, and assist in the development of Huntington's disease therapies.

Ø  Anti-Amyotrophic Lateral Sclerosis Drug(ALS) Drug Screening Service

Screening potential drugs that can delay motor neuron degeneration and improve survival rate in the C. elegans ALS model promotes therapeutic research on ALS.